Pacific Biosciences Earnings & Forecasts

Pacific Biosciences (PACB) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Aug 5, 2026	$-0.14	$-0.13	-7.69 %
Q1	May 7, 2026	$-0.12	$-0.14	14.3 %
Q4	Feb 12, 2026	$-0.12	$-0.16	25.0 %
Q3	Nov 5, 2025	$-0.12	$-0.15	20.0 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Aug 5, 2026	$39.01M	$40.97M	-4.79 %
Q1	May 7, 2026	$37.18M	$40.18M	-7.48 %
Q4	Feb 12, 2026	$44.65M	$41.83M	6.73 %
Q3	Nov 5, 2025	$38.44M	$40.08M	-4.10 %

Pacific Biosciences Guidance

Pacific Biosciences (PACB)는 8월 5, 2026에 fiscal year 2026에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $155M - $165M 범위로 예상했습니다.

이전 가이던스와 비교하여 Pacific Biosciences는 매출 전망치를 이전 범위인 하향 조정됨에서 $165M - $175M로 상향 조정했습니다.

Pacific Biosciences은 14과 1월 9, 2023 사이에 8월 5, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 4 times and lowered it 9 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$-0.13	$-0.14	$-0.16	$-0.15
Actual	$-0.14	$-0.12	$-0.12	$-0.12
Surprise	-7.69%	+14.3%	+25.0%	+20.0%
Revenue
Estimate	$41.0M	$40.2M	$41.8M	$40.1M
Actual	$39.0M	$37.2M	$44.6M	$38.4M
Surprise	-4.79%	-7.48%	+6.73%	-4.10%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$-0.13	$-0.13	$-0.12	$-0.13
Revenue
Consensus	$39.3M	$42.9M	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
Pacific Biosciences Lowers FY2026 Sales Guidance from $165.000M-$175.000M to $155.000M-$165.000M vs $166.790M Est

Pacific Biosciences (NASDAQ:PACB) lowers FY2026 sales outlook from $165.000 million-$175.000 million to $155.000 million-$165.000 million vs $166.790 million estimate.

Benzinga Newsdesk

PRO
Pacific Biosciences Q2 Adj. EPS $(0.14) Misses $(0.13) Estimate, Sales $39.007M Miss $40.067M Estimate

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 7.69 percent decrease over losses of $(0.13) per share

Benzinga Newsdesk

PRO
Pacific Biosciences Sees FY2026 Sales $165.000M-$175.000M vs $173.371M Est

Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371 million analyst estimate.

Benzinga Newsdesk

PRO
Pacific Biosciences Q1 Adj. EPS $(0.12) Beats $(0.14) Estimate, Sales $37.178M Miss $39.986M Estimate

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 7.69 percent. This is a 20 percent increase over losses of $(0.15) per share from

Benzinga Newsdesk

Insights into Pacific Biosciences Q4 Earnings

Benzinga Insights

PRO
Pacific Biosciences Q4 Adj. EPS $(0.12) Beats $(0.15) Estimate, Sales $44.645M Beat $42.530M Estimate

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 18.37 percent. This is a 40 percent increase over losses of $(0.20) per share from

Benzinga Newsdesk

Pacific Biosciences of California Inc